Information Services (III) – NobleCon 18 Presentation

Monday, April 25, 2022

Information Services (III)
NobleCon 18 Presentation

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 70 of the top 100 enterprises in the world, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. ISG CEO Michael Connors and CFO Bert Alfonso presented at NobleCon18. The transformation of the Company during COVID, ISG NEXT, and potential for acquisitions were highlighted in the presentation. A rebroadcast is available here.

    A Changing Model.  The COVID environment gave ISG the ability to transform the business towards two different segments, ISG Digital and ISG Enterprise, which gave companies the ability to choose which solution is needed, whether it is for more data analytics and cyber security (Digital) or Human Resources and Accounting (Enterprise). Combined with the iFlex working structure, ISG transformed the …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Item 9 Labs (INLB) – Notes from NobleCon18

Monday, April 25, 2022

Item 9 Labs (INLB)
Notes from NobleCon18

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. Item 9 Labs CFO Bobby Mikkelsen presented at NobleCon18. The Company’s franchising strategy and expansion were the main focus of the presentation. A rebroadcast is available here.

    Reg.  A Recap. Recall that in March of 2022, Item 9 Labs launched a regulation A offering of 28 million units of one share and one-half warrant, with a maximum proceed of $67.2 million. Management highlighted this offering in their presentation with the purpose of expanding the Unity Rd. franchise national footprint and growing the product into new markets, similarly to their expansion into New …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

One Stop Systems (OSS) – Notes from the NobleCon 18 Presentation

Monday, April 25, 2022

One Stop Systems (OSS)
Notes from the NobleCon 18 Presentation

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems. The product line of the company includes GPU Appliances, GPU Expansion, GPUs and co-processors, Flash storage arrays, Flash storage expansion, Servers, Disk Arrays, Desktop computing appliances, accessories and parts. The company delivers high-end technology to customers through the sale of equipment and software for use on their premises or through remote cloud access to secure data centres housing technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. One Stop Systems CEO David Raun and CFO John Morrison were hosted by us at NobleCon18. The major highlight from the presentation was their strategy in edge computing, particularly in AI Transportables. A rebroadcast is available here.

    A Growing Market.  Global Edge Computing is estimated to grow at a 38.4% CAGR to $61.1 billion in 2028 from the reported $6.3 billion in 2021. Alongside this, an estimated 75% of data processed will be through edge computing vs. 10% in 2018. This increase in data will help the Company, in our view, as the ever-growing amount of data in various industries will need to be processed in real-time …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

What Is a Tender Offer



Placing a Bid to Own a Public Company

 

A tender offer is a bid to purchase some or all the shares in a corporation. Most often these bids are a public invitation for shareholders to sell their positions to the bidding party, at a specified price, within a set timeframe.  As an inducement, the price offered is generally higher than the current market price. The offer is most often reliant on a minimum number of shares tendered, for example, 51% of outstanding to allow control.

A common variation of this is an exchange offer. This is a non-cash type of tender offer in which securities or other non-cash alternatives are offered in exchange for shares. When one company acquires another, it often does a share exchange in an exchange offer tender.

A publicly-traded company may present a tender offer for its own publicly held shares to either take themselves private or to reduce shares in the public’s hands and increase those in the corporation’s treasury.

Tender offers to acquire a company without the Board of Directors’ approval can be considered a hostile takeover. Hostile takeover acquirers in the past have included hedge funds, private equity firms, management-led investor groups, SPACs, and more recently a wealthy entrepreneur (Elon Musk).

 

Suggested Reading



Why Investors Monitor the Yield Curve and Yield Curve Changes



Why a Growing or Shrinking Fed Balance Sheet Can Impact Your Investments

 

Stay up to date. Follow us:

 

Release – NABs Leadership Foundation Selects Five Gray Television Stations As Finalists for 2022 Service to America Awards



NAB’s Leadership Foundation Selects Five Gray Television Stations As Finalists for 2022 Service to America Awards

Research, News, and Market Data on Gray Television

 

ATLANTA, April 21, 2022 (GLOBE NEWSWIRE) — The National Association of Broadcasters Leadership Foundation (“NABLF”) selected five television stations owned by Gray Television, Inc. (NYSE: GTN) as finalists for this year’s coveted Service to America Awards. The NABLF’s Service to America Awards recognize outstanding community service by local broadcasters and selects local radio and television stations and one group owner each year for their exemplary service to their communities. The winners in each category will be announced at an in-person gala in Washington, DC, on June 7, 2022.

In the Medium Market category, all three of the finalists selected by NABLF are Gray Television stations:

  • WMTV-TV (NBC) in Madison, Wisconsin, for its series “WMTV Diaper Drive Success”
  • WIS-TV (NBC) in Columbia, South Carolina, for its series “Families Helping Families;” and
  • WTOC-TV (CBS) in Savannah, Georgia, for its series “WTOC Tells Smart Women’s Stories and helps raise $139K to Fight Breast Cancer.”

In the Small Market category, two of the three finalists selected by NABLF are Gray Television stations:

  • WBNG-TV (CBS) in Binghamton, New York, for its series “WBNG Southern Tier Tuesdays;” and
  • KWQC-TV (NBC) in Davenport, Iowa, for its series “TV6 Real Conversations.”

“We are very proud of the great journalism across our company and industry that leads to actual results that improve local communities,” said Gray Executive Chairman and CEO Hilton H. Howell Jr. “We salute all of our honorees and especially the Gray Television stations for their continued commitment to quality journalism.”

About Gray:

Gray Television, Inc. is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets in the United States that serve 113 television markets reaching approximately 36 percent of US television households. This portfolio includes 80 markets with the top-rated television station and 100 markets with the first and/or second highest rated television station. We also own video program companies Raycom Sports, Tupelo Honey, and PowerNation Studios, as well as Third Rail Studios.


Contact Data

Gray Contacts:

Website: www.gray.tv
Bob Smith, Chief Operating Officer, 404-266-8333
Kevin P. Latek, Chief Legal and Development Officer, 404-266-8333

The Risky Position Elon Musk is Placing Himself In


Image: Daniel Oberhaus (Flickr)


What Would Failure Look Like to Elon Musk if He Buys Twitter?

 

Elon Musk is a winner. We witness his success daily, after all, he’s the richest person in the world. No one else can say that right now. But the challenges that took the South African-born immigrant from poor college student to his current status were not a straight line. And, taking over Twitter won’t be a sure win either, yet he is betting a lot of his previous financial success on his ability to acquire it and run it successfully.

As innovative, crafty and wealthy as Musk is, this potential acquisition of the social media giant, may put him in a political arena like he has never experienced before. Musk could find himself in a “deathmatch” with those that control the rules – in the ring with some that have been powerful enough to shape the version of Twitter that he is now trying to steer back toward inclusion.


Buying Twitter is not the Win

“Failure is an option here. If things are not failing you are not innovating.” – Elon Musk

The above Elon Musk quote was said prior to 2022. But, it is helpful to understand; he thrives on the challenge of doing things different, trying to do things that are meaningful. While many Elon fans are watching and expecting this larger-than-life person to handily succeed, he’s human and this deal must make him somewhat uncomfortable.

For Elon, success in buying Twitter, a company that had already reached a valuation well above his bid, is not the win. Transforming and re-innovating Twitter, against the wishes of many senior department heads, and against many political interests, is the ultimate goal. This could become a nightmare, after all, successfully sending a reusable rocket round trip into space is just physics, going against the grain of powerful people that want you to fail, goes beyond physics. It may present unseen, non-science challenges.


The Risk

Self-made billionaires don’t reach that category by depositing their paycheck into a JP Morgan Chase bank account to earn .01%. They get it by risking a great deal, by hiring the right team, putting in the necessary work, and maybe getting some breaks along the way. This is the largest acquisition financing ever by one person. It’s not chump change for Elon who is doing it his own unique way. He’s a proven manager, but he’ll be spreading himself thinner if he buys Twitter. And, may not find he is getting too many breaks from those in power positions.

More than two-thirds of the $46.5 billion financing package that Musk unveiled on Thursday (April 21) for his bid for Twitter would come from his own assets, the remainder would come from bank loans secured against Twitter’s assets. Typically, the majority of a buyout of this magnitude is funded by securing most of the debt against the acquired. Elon is taking two-thirds of the “lien” himself.

The banks approached showed concern that the regulators may reprimand them because of the size of the risk they would be putting on their balance sheet. The lack of cash flow from Twitter also created concern. They may have also been troubled that the would-be acquirer said he doesn’t care about the economics of the deal “at all.” Musk said that he was pursuing the acquisition because it was “extremely important to the future of civilization.”

The banks may have also pondered that Musk has suggested that he may move Twitter away from advertising, Twitter relies on ads for the majority of its revenue.

What amplifies the challenge for Tesla’s CEO is he has agreed to take out a $12.5 billion margin loan, secured against his Tesla (TSLA) stock to pay for a portion of the $33.5 billion. Were Tesla’s stock to drop by 40%, he would have to repay that margin loan, according to a regulatory filing.


The Twitter Side

Musk is the world’s richest person, with a net worth listed by Forbes of $270 billion. Yet most of his wealth is tied up in Tesla shares, and the proposed deal structure would dry up most of his available liquidity. Twitter’s board plans to ask Musk to provide more details on the source of the cash he has promised to deliver, according to people familiar with the matter.

Twitter’s board is preparing to reject Musk’s bid as too low by April 28, when the company is scheduled to report first-quarter earnings, sources have said.

Musk, who has amassed a stake in Twitter of 9.2%, said on Wednesday he’d be exploring taking a bid directly to Twitter’s shareholders via a tender
offer
. In that scenario, shareholders would not be able to sell their shares, because of the poison pill Twitter created. The shareholders would however be able to register their support for Musk’s bid.

Paul Hoffman

Managing Editor, Channelchek


Suggested Reading



Why Poison Pills Have Been Effective at Warding off Unsolicited Offers



Jack Dorsey, Corporate Boards, and Bad Apples





As Dorsey’s Tweet Exemplifies, NFT Market is Still Maturing



Placing a Bid to Own a Public Company

 

Sources

https://www.chase.com/content/dam/chase-ux/ratesheets/pdfs/rdny1.pdf

https://www.inc.com/alyssa-satara/in-2-sentences-elon-musk-explains-why-key-to-success-is-failure.html.

https://www.reuters.com/business/musk-tears-up-buyout-playbook-with-465-bln-twitter-financing-2022-04-22/

 

Stay up to date. Follow us:

 

Reading the Metaverses Virtual Fine Print


Image Credit: Duncan Rawlinson (Flickr)


Can You Truly Own Anything in the Metaverse? A Law Professor Explains How Blockchains and NFTs Don’t Protect Virtual Property

 

In 2021, an investment firm bought 2,000 acres of real estate for about US$4 million. Normally this would not make headlines, but in this case the land was virtual. It existed only in a metaverse platform called The Sandbox. By buying 792 non-fungible tokens on the Ethereum blockchain, the firm then owned the equivalent of 1,200 city blocks.

But did it? It turns out that legal ownership in the metaverse is not that simple.

The prevailing but legally problematic narrative among crypto enthusiasts is that NFTs allow true ownership of digital items in the metaverse for two reasons: decentralization and interoperability. These two technological features have led some to claim that tokens provide indisputable proof of ownership, which can be used across various metaverse apps, environments and games. Because of this decentralization, some also claim that buying and selling virtual items can be done on the blockchain itself for whatever price you want, without any person or any company’s permission.

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of João Marinotti, Associate Professor of Law, Indiana University.

 

Despite these claims, the legal status of virtual “owners” is significantly more complicated. In fact, the current ownership of metaverse assets is not governed by property law at all, but rather by contract law. As a legal scholar who studies property law, tech policy and legal ownership, I believe that what many companies are calling “ownership” in the metaverse is not the same as ownership in the physical world, and consumers are at risk of being swindled.


Purchasing in the Metaverse

When you buy an item in the metaverse, your purchase is recorded in a transaction on a blockchain, which is a digital ledger under nobody’s control and in which transaction records cannot be deleted or altered. Your purchase assigns you ownership of an NFT, which is simply a unique string of bits. You store the NFT in a crypto wallet that only you can open, and which you “carry” with you wherever you go in the metaverse. Each NFT is linked to a particular virtual item.

It is easy to think that because your NFT is in your crypto wallet, no one can take your NFT-backed virtual apartment, outfit or magic wand away from you without access to your wallet’s private key. Because of this, many people think that the NFT and the digital item are one and the same. Even experts conflate NFTs with their respective digital goods, noting that because NFTs are personal property, they allow you to own digital goods in a virtual world.

However, when you join a metaverse platform you must first agree to the platform’s terms of service, terms of use or end user license agreement. These are legally binding documents that define the rights and duties of the users and the metaverse platform. Unfortunately, and unsurprisingly, almost no one actually reads the terms of service. In one study, only 1.7% of users found and questioned a “child assignment clause” embedded in a terms of service document. Everyone else unwittingly gave away their first-born child to the fictional online service provider.

It is in these lengthy and sometimes incomprehensible documents where metaverse platforms spell out the legal nuances of virtual ownership. Unlike the blockchain itself, the terms of service for each metaverse platform are centralized and are under the complete control of a single company. This is extremely problematic for legal ownership.

Interoperability and portability are defining features of the metaverse, meaning you should be able to carry your non-real-estate virtual property – your avatar, your digital art, your magic wand – from one virtual world to another. But today’s virtual worlds are not connected to one another, and there is nothing in an NFT itself that labels it as, say, a magic wand. As it stands, each platform needs to link NFTs to their own proprietary digital assets.

 

Virtual Fine Print

Under the terms of service, the NFTs purchased and the digital goods received are almost never one and the same. NFTs exist on the blockchain. The land, goods and characters in the metaverse, on the other hand, exist on private servers running proprietary code with secured, inaccessible databases.

This means that all visual and functional aspects of digital assets – the very features that give them any value – are not on the blockchain at all. These features are completely controlled by the private metaverse platforms and are subject to their unilateral control.

Because of their terms of service, platforms can even legally delete or give your items away by delinking the digital assets from their original NFT identification codes. Ultimately, even though you may own the NFT that came with your digital purchase, you do not legally own or possess the digital assets themselves. Instead, the platforms merely grant you access to the digital assets and only for the length of time they want.

For example, on one day you might own a $200,000 digital painting for your apartment in the metaverse, and the next day you may find yourself banned from the metaverse platform, and your painting, which was originally stored in its proprietary databases, deleted. Strictly speaking, you would still own the NFT on the blockchain with its original identification code, but it is now functionally useless and financially worthless.

Virtual
items like this avatar are sold in NFT marketplaces. Nescolet/Flickr

While admittedly jarring, this is not a far-fetched scenario. It might not be a wise business move for the platform company, but there’s nothing in the law to prevent it. Under the terms of use and premium NFT terms of use governing the $4 million’s worth of virtual real estate purchased on The Sandbox, the metaverse company – like many other NFT and metaverse platforms – reserves the right at its sole discretion to terminate your ability to use or even access your purchased digital assets.

If The Sandbox “reasonably believes” you engaged in any of the platform’s prohibited activities, which require subjective judgments about whether you interfered with others’ “enjoyment” of the platform, it may immediately suspend or terminate your user account and delete your NFT’s images and descriptions from its platform. It can do this without any notice or liability to you.

In fact, The Sandbox even claims the right in these cases to immediately confiscate any NFTs it deems you acquired as a result of the prohibited activities. How it would successfully confiscate blockchain-based NFTs is a technological mystery, but this raises further questions about the validity of what it calls virtual ownership.

 

Legally Binding

As if these clauses weren’t alarming enough, many metaverse platforms reserve the right to amend their terms of service at any time with little to no actual notice. This means that users would need to constantly refresh and reread the terms to ensure they do not engage in any recently banned behavior that could result in the deletion of their “purchased” assets or even their entire accounts.

 

Suggested Reading



Why the Metaverse is Attracting Traditional Professions



The Metaverse vs Virtual Reality, Two Different Worlds





NobleCon18 Brought Media Experts Together to Discuss the Metaverse, Here’s What Happened



Why the Metaverse Matters

 

Stay up to date. Follow us:

 

Psychedelic Medicine a Revolution for the Mind


Image Credit: Bridget Samuels (Flickr)


The NobleCon18 Panel of Psilocybin Experts Clearly Demonstrated Potential Medical Benefits

 

The panel discussion on psilocybin at NobleCon18 was led off by one of the most credible people I have heard speaking at any investor conference about the possibilities of their industry. He was a former professional athlete whose brain function, as a result of his career choice, left him a shell of who he had been. On stage with three other CEOs, from different corners of this growing mental health field, the panel provided excitement for both the future of helping people overcome brain health issues and providing investment opportunities in an industry that is sure to mushroom.

The Line-up

Eric Bolling, TV Personality and Host of Eric Bolling The Balance (Moderator)

Daniel Corcillo, CEO, Wesana Health (Panelist)

Evan Levine, CEO, Psybio Therapeutics (Panelist)

Ben Lightburn, CEO, Filament Health (Panelist)

Justin Dye, CEO, Schwazze (Panelist)

 

Expert Thoughts

Daniel Corcillo spoke directly to the audience at the open as someone who has benefitted from psilocybin treatments. Corcillo, who is now the CEO of Wesana Health (WSNAF) had played professional hockey for 12 years. During that time he had suffered seven concussions. This forced Dan’s early retirement. As a husband and dad, he pushed himself to find the cure for his brain fog, depression, and dementia-like symptoms.

After five years of trying all the clinical therapies that modern medicine has to offer, he sought supervised treatment with psilocybin. Dan laid out for the NobleCon investor audience, in the kind of detail that demonstrated that his mind was now extremely sharp, his very short successful treatment. A treatment that he said, after two weeks, had him “feeling the way I should.” And after six months having bloodwork that showed everything had equalized.


From Left to Right: Justin Dye (SHWZ), Ben Lightburn (FLHLF), Evan Levine (PSYBF), Dan Corcillo (WSNAF) and Eric Bolling (Newsmax)

 

It was after Mr. Corcillo shared his story that prompted him to become involved in the business itself to help others, that he was joined by Evan Levine of Psybio Therapeutics (PSYBF), Ben Lightburn of Filament Health (FLHLF), and Justin Dye of Schwazze (SHWZ).

The discussion ventured beyond mushrooms to at times include other psychedelic drugs and highly regulated substances like, MDNA, LSD, and Cannabis. 

Mr. Levine’s company Psybio creates biosynthetic psilocybin in a lab at a fraction of the price of growing mushrooms. From a medical treatment perspective, he and his firm emphasize the benefit of knowing exactly what the measurement is for dosing.

While agreeing that precise dosing measurements are important, Mr. Lightburn expressed that botanicals (not synthetic) allow all the chemicals to make it into the final product. He said this provides what he called the “entourage effect.” Other panelists referred to the interplay between chemicals as the “innate synergy.”                         

We learned from Mr. Dye that he does not expect the “magic mushroom” market to eat into the cannabis market either from a recreational or medicinal standpoint. He explained that it is additive as medical caregivers operating on the West coast now have options as to how to best treat individual patients.

The Industry

The antidepressant industry is $100 billion and growing. SSRIs have been the standard of care since the 1980s and are fraught with problems. Opioid use is a problem that is not going away, and more research should be done concerning this problem.

Having a legal framework under which to operate could allow for faster research on products that don’t have the addictive tendencies of problem drugs, have a history of safety, and are not prone to overdosing.

The industry of providing psilocybin therapeutic centers could create the need for many therapists, as the oversight is hands-on and interactive for about 42 hours.

While most panelists see more decriminalization of magic mushrooms locally, they don’t expect full legalization, especially as it relates to recreational use. One panelist did point out that in Vancouver, un-regulated mushrooms are sold openly and even advertised in store windows.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:



Psychedelic Laws and Investments May Follow Cannabis’ Success



The Lasting Benefit of Psilocybin Treatment for Extreme Depression





Mapping Psilocybin’s Effect on the Brain



Acceptance of Psychedelics for Wellness and Recreation

 

Stay up to date. Follow us:

 

Evaluating Gold Royalty Companies to Gain Exposure to Precious Metals


Image: James St. John (Flickr)


Adding Precious Metal Exposure to Your Portfolio? Gold Royalty Company Considerations

 

Investors have many options to gain exposure to gold. They may purchase gold bullion, gold coins, gold exchange-traded funds (ETF) and mutual funds, gold mining companies, or gold futures and options. Publicly traded equities of gold producers and royalty companies may offer an attractive way to invest given the disproportionate percentage impact higher commodity prices may have on a company’s bottom line and valuation for a given percentage increase in the commodity itself. While most investors are likely familiar with mining companies and how they operate, royalty companies may be less familiar.


What is a Gold Royalty?

A gold royalty is a contract that gives the owner the right to a percentage of gold production or revenue. Since royalties typically cover the life of a mine, gold royalty companies benefit from the exploration upside that may extend the life of a mine and thus increase the amount of gold or revenue they receive from the mining company at no additional cost.

There are several ways to generate royalties. First, royalty businesses may help finance a development project in exchange for a royalty. Second, a royalty business may purchase existing royalties from third parties, and 3) a royalty company may take a property that they already own, sell it to a mining company, and retain a royalty on the property.

There are several types of royalties. The two most common are NSR and NPI royalties. A net smelter return (NSR) royalty is an agreement where the mining company agrees to pay the royalty owner a percentage of the revenue, less refining and smelting costs. A net profit interest (NPI) royalty entitles the royalty owner to a percentage of the profit from a mine.

A stream is a purchase agreement that provides the owner of the stream, in exchange for an upfront payment, the right to purchase all or a portion of one or more metals produced from a mine at a negotiated price for the life of the agreement. The negotiated price is generally at a significant discount to the spot price.


Royalty Company Advantages

Compared with investing in gold production companies, royalty businesses generally benefit from low overhead costs, geographically diversified asset portfolios, and exposure to multiple operators.  Additionally, they avoid costly exploration expense which is borne by operators while sharing the benefit and upside of exploration investment in properties where they retain a royalty interest.  Like mining companies, royalty businesses offer greater leverage to changes in gold prices than investing in bullion.  Lastly, royalty businesses generally seek to build portfolios of producing royalties that support dividend payments to shareholders. 

Investors in gold royalty companies understand that revenues increase with rising gold prices, increasing production on its royalty properties, and a growing royalty portfolio, while costs remain relatively fixed and stable. These various scenarios position royalty companies to thrive in good markets and weather more challenging sets of circumstances.

As a royalty company grows, it offers the potential for multiple expansion, dividend payments, and the ability to execute larger transactions which could accelerate its growth. Junior royalty companies generally perform well in their early years since they can grow rapidly based on an increasing capacity to transact larger deals. Additionally, junior royalty companies may become attractive acquisition candidates for a larger royalty company seeking to enlarge its royalty portfolio.

Investor Considerations

It is important for investors to keep several factors in mind when conducting due diligence on prospective royalty company investments. These include: 1) management, 2) asset portfolio, 3) asset quality, 4) jurisdiction, and 5) valuation.

Management Should you bet on the horse or the jockey? It is important to evaluate management’s history and track record of creating value for shareholders. Does the management team reflect a balance of technical, financial, legal, and capital markets expertise? Is the board of directors comprised mostly of independent directors who provide a diversity of relevant experience and perspectives? Do they articulate clear objectives, and is their business model sound? Most importantly, do they focus on areas they know and employ a disciplined growth strategy, or are they seeking growth at any price?

Asset Portfolio – How is the company’s asset portfolio balanced between royalties that are producing cash flow streams versus royalties that are expected to produce cash flow within five years and/or longer?

Asset QualityBecause royalty companies have little control over the decisions of the mining companies that control the properties on which the royalty interest is held, it is important for investors to evaluate the operators associated with the properties in the royalty portfolio. Are they well-capitalized major mining companies or small start-ups? Additionally, it is helpful to evaluate mineral resource estimates associated with properties in the portfolio and the operators’ plans for development.     

JurisdictionWhile geographic diversity is a selling point for most royalty companies, it is often helpful to consult the Fraser Institute’s Annual Survey of Mining Companies to check if royalty interests are in favorable mining jurisdictions versus high-risk areas.

ValuationRoyalty companies are often valued based on price to net asset value. Net asset value is the net present value (NPV) or discounted cash flow (DCF) of all future cash flow of a mining asset, less any debt plus cash. Price to net asset value is the company’s market capitalization divided by the net present value of all mining assets minus net debt. For those that pay a dividend, investors may also compare dividend growth rates and yield. Larger companies generally trade at higher valuation multiples which generally increase with scale due to lower perceived risk due to greater asset diversification and a proven track record of growth. As royalty companies grow, they may be able to establish and grow dividends to shareholders, offer greater liquidity due to listings on major exchanges, and benefit from broader research. Some may also benefit from their inclusion in stock indices. For those that pay a dividend, it is important to know whether the dividend is paid from operating cash flow or whether the company is borrowing to pay the dividend.


Take-Away

Just as with other classes of equities, mining royalty company investing has categories and nuances within those categories that separate one from the other. Investors should be mindful of each of these and find respected sources of information on the particular names they are considering. Channelchek can be a goldmine of information when searching for companies, understanding their business, and looking at their numbers.


Suggested Reading



Will the Fed Push Gold and Crypto Up by Raising its Inflation Target?



Why Poison Pills Have Been Effective at Warding off Unsolicited Offers





April 20 Growing as a Day of Cannabis Recognition



What Media Experts Expect from the Metaverse

 

Sources

4 Reasons Why We Believe in Royalty Companies

How Precious Metals Royalty and Streaming Companies Create Value

Streaming & Royalty Companies: Mutually Beneficial Arrangements for Everyone, including Investors

 

Stay up to date. Follow us:

 

What is the Feds Beige Book? (In 500 Words or Less)



Why the Beige Book Takes on Added Importance in Times of Growing Economic Uncertainty

 

The Beige Book, more technically known as the Summary of Commentary on Current Economic Conditions, is a report compiled by the United States Federal Reserve Board (The Fed) eight times each year. The information a review of economic conditions within the Feds 12 banking districts. The information discusses the business activity in the area, the trends, and how tight labor markets are.

Information in the Beige Book is divided by industry, including real estate, tourism, agriculture, financial services, manufacturing, and high-tech. Trends in employment, prices, and wages for each of the 12 districts is also a regular part of the reporting.

Additionally, the districts comment on how the businesses of their region are impacted by national and international trends. The Beige Book will also examine how local businesses are affected by changes in exchange rates, oil prices, and inflation.


Common Beige Book Usage

If the district overall reports show economic activity is slowing, the FOMC may begin to lean toward easing monetary policy, to stimulate economic strength.

The FOMC may also discern from the districts an overheating national economy inflationary risks headed higher than the Fed target. In this case they will discuss at the FOMC meeting hitting the economic brakes with a contractionary strategy. This could include pulling money out of the economy and raising interest rates. 

The Beige Book allows investors and analysts to see a report that the FOMC will use to help guide their hand. Many view it as a lagging indicator as the information is looking in the rearview mirror. Other Fed watchers consider the Beige Book contents a leading economic indicator because it influences the FOMC’s decisions.

The most critical change the Fed may take after reviewing economic detail of the entire country and the business is adjustments to the Fed Funds rate. Surprises in the report has the ability to cause the markets (bond and stock) to suddenly turn.


Suggested Reading



What is the Yield Curve



What is the PCE Index?

 

Stay up to date. Follow us:

 

Release – CoreCivic Announces 2022 First Quarter Earnings Release and Conference Call Dates



CoreCivic Announces 2022 First Quarter Earnings Release and Conference Call Dates

Research, News, and Market Data on CoreCivic

 

BRENTWOOD, Tenn., April 21, 2022 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2022 first quarter financial results after the market closes on Wednesday, May 4, 2022.  

A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 5, 2022, and will be accessible through the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. The live broadcast can also be accessed by dialing 888-882-4478 in the U.S. and Canada, including the confirmation passcode 8967211. An online replay of the call will be archived on our website promptly following the conference call. In addition, there will be a telephonic replay available beginning at 1:15 p.m. central time (2:15 p.m. eastern time) on May 5, 2022, through 1:15 p.m. central time (2:15 p.m. eastern time) on May 13, 2022. To access the telephonic replay, dial 888-203-1112 in the U.S. and Canada. International callers may dial +1 719-457-0820 and enter passcode 8967211.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024

Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1



electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

News and Market Data on electroCore

 

ROCKAWAY, N.J.
April 21, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire™ in patients admitted to the hospital for treatment of COVID-19. 

The SAVIOR-1 trial was conducted by principal investigator Dr.  Carlos Tornero, Head of the 
Department of Anesthesiology, Resuscitation and Pain Therapeutics of the Hospital Clínico Universitario de 
Valencia, Spain, between 
April 2020 and 
February 2021. The trial targeted patients over 18 years of age and enrolled 110 patients, randomly assigned, with 55 patients in each group. Of the 110 patients, 97 patients (47 in the nVNS treatment group, 50 in the control group) provided baseline demographic and medical history data and were the evaluable population. The study evaluated the safety and feasibility of nVNS when administered in addition to the then-standard of care in patients hospitalized with active SARS-CoV-2 infection compared with the standard of care alone.

The study identified significant treatment differences for certain biomarkers of inflammation. Decreases from baseline in C-reaction protein (CRP) levels were significantly greater in the nVNS treatment group as compared to the control group throughout the five-day period combined (p=0.011) and on day 5 compared to the day 1 baseline period alone (p=0.015). On day 1, CRP levels were highly elevated for 90% of all subjects, but by days 3 and 5, the percentage of subjects with normal CRP levels improved markedly in the nVNS group with day 3 CRP levels at 17.9% vs. 52.2% in the control (p=0.010). Additionally, the nVNS group had a significantly greater decrease from baseline in procalcitonin level at day 5 (p=0.012) as compared to the control group. Increased levels of CRP, procalcitonin, and d-dimer have all been reported to be associated with more severe disease and the lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms.

nVNS was well tolerated with no major device-related adverse events and the therapy was administered three times daily to most patients as outlined in the study protocol.

“We are thrilled that the SAVIOR-1 article has been peer-reviewed and published in the Frontiers in Neurology journal,” mentioned Dr.  Peter Staats, Chief Medical Officer at electroCore. “We are encouraged by this publication as Frontier’s rigorous process for peer-reviewing articles further strengthens and validates our nVNS technology and its relevancy and potential to mitigate some of the symptoms associated with COVID-19.” 

The Frontiers in Neurology publication is available here.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Adolescent patients with congenital cardiac issues
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

For more information, please visit gammaCore.com

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects, the results from investigator-initiated trials, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the
SEC, available at www.sec.gov.

Contact:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Release – Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases



Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to evaluate the potential of Cocrystal’s 3CL protease inhibitors for the treatment of COVID-19. Cocrystal applied its proprietary drug discovery platform technology to develop novel, broad-spectrum SARS-CoV-2 3CL protease inhibitors. Under the NIAID collaboration, Cocrystal has provided its 3CL protease inhibitors, and the NIAID will be responsible for in vitro and in vivo studies evaluating the antiviral activity of the compounds.

“We are pleased to collaborate with NIAID to further evaluate Cocrystal’s SARS-CoV-2 3CL protease inhibitors. Cocrystal is committed to identifying safe and effective treatments for infectious diseases including those caused by SARS-CoV-2 and other coronaviruses,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “We are pleased that the NIAID has researched our novel, broad-spectrum protease inhibitors and has determined that further evaluation in an animal model is warranted. Studies to date show that our protease inhibitors exhibit superior in vitro potency against SARS-CoV-2 and variants of concern including Omicron.”

A division of the National Institutes of Health (NIH), NIAID conducts and supports basic and applied research to better understand, treat and ultimately prevent infectious, immunologic and allergic diseases. Dr. Anthony S. Fauci, M.D. was appointed Director of the NIAID in 1984. More information is available at niaid.nih.gov/.

About Cocrystal SARS-CoV-2/Coronavirus Programs
Cocrystal is developing COVID-19 drug candidates that specifically target proteins involved in viral replication. Despite the various strains of virus that may exist or emerge, these enzymes are required for viral replication and are essentially similar (highly conserved) among all strains. By targeting these highly conserved regions of the replication enzymes, Cocrystal’s antiviral compounds are designed and tested to be effective against major virus strains. Additionally, Cocrystal believes it is possible to develop an effective treatment for all coronavirus diseases including COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The Company’s main SARS-CoV-2 protease inhibitors showed potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our collaboration with NIAID and our ability to develop an effective treatment for all coronavirus diseases. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of the COVID-19 pandemic and the Russian invasion of Ukraine on the global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, the results of NIAID’s preclinical research of our 3CL protease inhibitors for the treatment of COVID-19, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.